Cannara Biotech (STU:8CB0) Change In Receivables : €-1.39 Mil (TTM As of Aug. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Change In Receivables?

Cannara Biotech's change in receivables for the quarter that ended in Aug. 2024 was €-0.83 Mil. It means Cannara Biotech's Accounts Receivable increased by €0.83 Mil from May. 2024 to Aug. 2024 .

Cannara Biotech's change in receivables for the fiscal year that ended in Aug. 2024 was €-1.37 Mil. It means Cannara Biotech's Accounts Receivable increased by €1.37 Mil from Aug. 2023 to Aug. 2024 .

Cannara Biotech's Accounts Receivable for the quarter that ended in Aug. 2024 was €8.66 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cannara Biotech's Days Sales Outstanding for the three months ended in Aug. 2024 was 51.65.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cannara Biotech's liquidation value for the three months ended in Aug. 2024 was €-20.15 Mil.

Cannara Biotech Change In Receivables Historical Data

The historical data trend for Cannara Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Change In Receivables Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Change In Receivables

Get a 7-Day Free Trial

0.30

-1.72

-3.96

-0.83

-1.37

Cannara Biotech Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
Change In Receivables	Get a 7-Day Free Trial															-0.28	0.29	-1.07	0.22	-0.83

Cannara Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.39 Mil.

Cannara Biotech (STU:8CB0) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cannara Biotech's Days Sales Outstanding for the quarter that ended in Aug. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8.66	/	15.301	*	91
=	51.65

2. In Ben Graham's calculation of liquidation value, Cannara Biotech's accounts receivable are only considered to be worth 75% of book value:

Cannara Biotech's liquidation value for the quarter that ended in Aug. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.397	-	44.349	+	0.75 * 8.66	+	0.5 * 26.618
=	-20.15

Cannara Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

LOVFF:USA LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Cannara Biotech Headlines

No Headlines